Ocugen, Inc.
NASDAQ:OCGNBiotechnology
+$0.03 today
- Market cap
- $250.82M
- Beta
- 2.21
- P/E (TTM)
- -5.6
- EPS (TTM)
- -$0.22
Volume 5.83M
Average 7.51M
OCGN Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Ocugen, Inc.NASDAQ: OCGN
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $3.4M rose 80.3% year over year, ahead of the +22.1% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 69.7% from the prior quarter. Over 3 fiscal years it compounded at -9.9% a year.
Context
- Stock-based compensation amounted to 174.6% of revenue in FY2025, down 8.5 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +80.3% holds above the trailing-twelve-month pace of +22.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 7.71M USD
- Year-over-year change
- +3.8%
- 4-year CAGR
- +2.6%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.71M | +3.8% |
| FY2024 | 2024-12-31 | 7.43M | -19.4% |
| FY2023 | 2023-12-31 | 9.22M | -12.6% |
| FY2022 | 2022-12-31 | 10.54M | +51.5% |
| FY2021 | 2021-12-31 | 6.96M | — |
Stock-Based Compensation vs competitors
How OCGN compares with its peers on the latest reported figures
- OCGN's LTM Mar 2026 stock-based compensation of $9.22M is the 7th largest of the 10 companies compared; the peer median is $12.55M.
- Its year-over-year change of +22.1% is the 2nd highest of 10, against a peer median of -4.7%.
- Stock-based compensation amounts to 206.5% of revenue for OCGN, versus a peer median of 31.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $36.4M | -7.4% | +94.0% | 492.0% |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $27.96M | -33.3% | +53.3% | — |
| LTM Mar 2026 | $13.16M | -4.7% | -2.3% | — | |
| LTM Mar 2026 | $12.63M | +26.4% | -48.5% | 16.0% | |
| LTM Mar 2026 | $12.55M | +2.5% | +2.8% | 18.0% | |
| LTM Mar 2026 | $10.93M | +20.5% | +16.2% | — | |
| LTM Mar 2026 | $9.22M | +22.1% | -9.9% | 206.5% | |
| LTM Mar 2026 | $5.74M | +13.3% | — | 58.0% | |
| LTM Mar 2026 | $4.71M | -8.3% | +3.5% | 31.8% | |
| LTM Mar 2026 | $3.41M | -69.9% | +124.6% | — | |
| Peer median (excluding OCGN) | $12.55M | -4.7% | +9.9% | 31.8% | |
Competitors are the stored peer set for OCGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (58.37M) | (86.8M) | (63.08M) | (54.05M) | (67.85M) |
| Depreciation & Amortization | 229K | 480K | 704K | 1.97M | 2.39M |
| Deferred Income Tax | (52K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.96M | 10.54M | 9.22M | 7.43M | 7.71M |
| Change in Working Capital | 2.49M | 9.2M | (13.16M) | 3.67M | (523K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.5M | 0 | 0 | 0 | 0 |
| Other Working Capital | (1.01M) | 9.2M | (13.16M) | 3.67M | (523K) |
| Other Non-Cash Items | 799K | 6.51M | 4.26M | (1.15M) | 1.31M |
| Operating Cash Flow | (47.94M) | (60.08M) | (62.05M) | (42.14M) | (56.96M) |
| Capital Expenditures | (939K) | (4.46M) | (10.48M) | (3.39M) | (185K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (13.27M) | (3.95M) | 0 | 0 |
| Sales of Investments | 0 | 0 | 17.5M | 0 | 0 |
| Other Investing Activities | (877K) | 761K | 0 | 0 | (126K) |
| Investing Cash Flow | (1.82M) | (16.97M) | 3.08M | (3.39M) | (311K) |
| Debt Repayment | (10K) | 500K | 500K | 30M | (1M) |
| Common Stock Issued | 129.21M | 59.57M | 20.8M | 38.56M | 18.33M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (8.53M) | (592K) | (68K) | (3.7M) | 0 |
| Financing Cash Flow | 120.68M | 59.48M | 20.88M | 64.86M | 17.33M |
| Effect of Forex Changes | (325) | 25K | (5K) | 28K | 13K |
| Net Change in Cash | 70.92M | (17.55M) | (38.1M) | 19.36M | (39.93M) |
| Free Cash Flow | (48.88M) | (64.54M) | (72.53M) | (45.53M) | (57.15M) |
Ocugen, Inc.
NASDAQ:OCGN
Intrinsic Alpha fair value
Locked
Current Price
$0.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.